Corporate Finance Staff Learn New Tax Policy
Release time:
2020-08-14
Company Financial Staff Learn New Tax Policies
News # July 2 , the Finance Department of the Group Company organized a meeting of financial staff of subordinate enterprises to exchange recent financial work and to study and discuss newly introduced or soon-to-be-implemented tax policies such as simplified value-added tax.
The meeting was presided over by Wu Defu, manager of the finance department of the group company. The financial personnel of each unit had a comprehensive exchange on the problems existing in the financial and tax work of the unit and the matters to be communicated. They also studied the latest simplified value-added tax policy and the announcement of the State Administration of Taxation on issues related to the issuance of value-added tax invoices.
The Ministry of Finance and the State Administration of Taxation issued a notice on 4 July 28 . Starting from 2017 7 1 , the VAT rate structure will be simplified, the VAT rate of 13% will be canceled, and the VAT rate of the original 13% will be simplified to 11% . 5 March 19 , in order to further strengthen the management of value-added tax invoices, ensure the smooth implementation of the pilot project of changing business tax to value-added tax, protect the legitimate rights and interests of taxpayers, and create a healthy and fair tax environment, the State Administration of Taxation made clear the issues related to the issuance of value-added tax invoices by Announcement No. 16 of 2017 . The announcement clearly stated that the ordinary invoice did not fill in the taxpayer identification number of the purchaser and could not be deducted before tax, and the contents of the VAT invoice issued by the seller should be truthfully issued in accordance with the actual sales situation. It was called the "strictest invoice order" by the people ". The implementation of these new tax policies is bound to have an impact on corporate finance and taxation. Lan Xiaolong, financial director of
group company, stressed at the meeting that strengthening the audit of substantive elements related to enterprise expenditure is an important part of the enterprise's continuous improvement of its internal control system. at the same time, it is also an important basis for the enterprise income tax law to judge whether pre-tax deduction is allowed, and it is an important condition to prove whether the enterprise expenditure is related to the enterprise's income and whether it is reasonable. He analyzed the current internal and external economic environment of the enterprise, and required the company's financial personnel to strengthen the study of relevant policies and timely grasp the relevant trends; constantly learn management accounting knowledge, combined with the current development trend of cloud computing and big data, strive to improve their business level, so as to better solve the problems in the process of financial management, better cope with the new changes in financial management, and meet the high-level requirements for financial personnel in the new period.
Financial personnel of overseas enterprises such as Daye Peak and Yunnan Peak participated in the study through the teleconference system. (Li Xia Zhou Huijuan)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page